Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

Alessandra Trojani; Ester Pungolino; Giuseppe Rossi; Mariella D'Adda; Milena Lodola; Barbara Di Camillo; Alessandra Perego; Mauro Turrini; Ester Orlandi; Lorenza Borin; Alessandra Iurlo; Simona Malato; Francesco Spina; Maria Luisa Latargia; Francesco Lanza; Salvatore Artale; Michela Anghilieri; Maria Cristina Carraro; Gabriella De Canal; Enrica Morra; Roberto Cairoli

doi:10.3233/CBM-170209

Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

Alessandra Trojani, Ester Pungolino, Giuseppe Rossi, Mariella D'Adda, Milena Lodola, Barbara Di Camillo, Alessandra Perego, Mauro Turrini, Ester Orlandi, Lorenza Borin, Alessandra Iurlo, Simona Malato, Francesco Spina, Maria Luisa Latargia, Francesco Lanza, Salvatore Artale, Michela Anghilieri, Maria Cristina Carraro, Gabriella De Canal, Enrica MorraRoberto Cairoli

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined.

OBJECTIVE: We undertook a gene expression profiling (GEP) study of selected bone marrow (BM) CD34+/lin- cells of chronic-phase CML patients at diagnosis and after 12 months of TKI nilotinib to investigate molecular signatures characterizing both conditions.

Original language	English
Pages (from-to)	41-53
Number of pages	13
Journal	Cancer Biomarkers
Volume	21
Issue number	1
DOIs	https://doi.org/10.3233/CBM-170209
Publication status	Published - 2018

Keywords

Antigens, CD34/blood
Bone Marrow Cells/metabolism
Gene Expression Profiling/methods
Gene Expression Regulation, Leukemic/drug effects
Humans
Leukemia, Myeloid, Chronic-Phase/blood
Leukocyte Count
Protein-Tyrosine Kinases/therapeutic use
Pyrimidines/therapeutic use
Time Factors
Treatment Outcome

Access to Document

10.3233/CBM-170209

Cite this

Trojani, A., Pungolino, E., Rossi, G., D'Adda, M., Lodola, M., Camillo, B. D., Perego, A., Turrini, M., Orlandi, E., Borin, L., Iurlo, A., Malato, S., Spina, F., Latargia, M. L., Lanza, F., Artale, S., Anghilieri, M., Carraro, M. C., Canal, G. D., ... Cairoli, R. (2018). Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment. Cancer Biomarkers, 21(1), 41-53. https://doi.org/10.3233/CBM-170209

Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment. / Trojani, Alessandra; Pungolino, Ester; Rossi, Giuseppe; D'Adda, Mariella; Lodola, Milena; Camillo, Barbara Di; Perego, Alessandra; Turrini, Mauro; Orlandi, Ester; Borin, Lorenza; Iurlo, Alessandra; Malato, Simona; Spina, Francesco; Latargia, Maria Luisa; Lanza, Francesco; Artale, Salvatore; Anghilieri, Michela; Carraro, Maria Cristina; Canal, Gabriella De; Morra, Enrica; Cairoli, Roberto.

In: Cancer Biomarkers, Vol. 21, No. 1, 2018, p. 41-53.

Research output: Contribution to journal › Article › peer-review

Trojani, A, Pungolino, E, Rossi, G, D'Adda, M, Lodola, M, Camillo, BD, Perego, A, Turrini, M, Orlandi, E, Borin, L, Iurlo, A, Malato, S, Spina, F, Latargia, ML, Lanza, F, Artale, S, Anghilieri, M, Carraro, MC, Canal, GD, Morra, E & Cairoli, R 2018, 'Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment', Cancer Biomarkers, vol. 21, no. 1, pp. 41-53. https://doi.org/10.3233/CBM-170209

Trojani, Alessandra ; Pungolino, Ester ; Rossi, Giuseppe ; D'Adda, Mariella ; Lodola, Milena ; Camillo, Barbara Di ; Perego, Alessandra ; Turrini, Mauro ; Orlandi, Ester ; Borin, Lorenza ; Iurlo, Alessandra ; Malato, Simona ; Spina, Francesco ; Latargia, Maria Luisa ; Lanza, Francesco ; Artale, Salvatore ; Anghilieri, Michela ; Carraro, Maria Cristina ; Canal, Gabriella De ; Morra, Enrica ; Cairoli, Roberto. / Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment. In: Cancer Biomarkers. 2018 ; Vol. 21, No. 1. pp. 41-53.

@article{6940d0245feb4f1d85cce275a21e9e7b,

title = "Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment",

abstract = "BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined.OBJECTIVE: We undertook a gene expression profiling (GEP) study of selected bone marrow (BM) CD34+/lin- cells of chronic-phase CML patients at diagnosis and after 12 months of TKI nilotinib to investigate molecular signatures characterizing both conditions.",

keywords = "Antigens, CD34/blood, Bone Marrow Cells/metabolism, Gene Expression Profiling/methods, Gene Expression Regulation, Leukemic/drug effects, Humans, Leukemia, Myeloid, Chronic-Phase/blood, Leukocyte Count, Protein-Tyrosine Kinases/therapeutic use, Pyrimidines/therapeutic use, Time Factors, Treatment Outcome",

author = "Alessandra Trojani and Ester Pungolino and Giuseppe Rossi and Mariella D'Adda and Milena Lodola and Camillo, {Barbara Di} and Alessandra Perego and Mauro Turrini and Ester Orlandi and Lorenza Borin and Alessandra Iurlo and Simona Malato and Francesco Spina and Latargia, {Maria Luisa} and Francesco Lanza and Salvatore Artale and Michela Anghilieri and Carraro, {Maria Cristina} and Canal, {Gabriella De} and Enrica Morra and Roberto Cairoli",

year = "2018",

doi = "10.3233/CBM-170209",

language = "English",

volume = "21",

pages = "41--53",

journal = "Cancer Biomarkers",

issn = "1574-0153",

publisher = "IOS Press",

number = "1",

}

TY - JOUR

T1 - Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

AU - Trojani, Alessandra

AU - Pungolino, Ester

AU - Rossi, Giuseppe

AU - D'Adda, Mariella

AU - Lodola, Milena

AU - Camillo, Barbara Di

AU - Perego, Alessandra

AU - Turrini, Mauro

AU - Orlandi, Ester

AU - Borin, Lorenza

AU - Iurlo, Alessandra

AU - Malato, Simona

AU - Spina, Francesco

AU - Latargia, Maria Luisa

AU - Lanza, Francesco

AU - Artale, Salvatore

AU - Anghilieri, Michela

AU - Carraro, Maria Cristina

AU - Canal, Gabriella De

AU - Morra, Enrica

AU - Cairoli, Roberto

PY - 2018

Y1 - 2018

N2 - BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined.OBJECTIVE: We undertook a gene expression profiling (GEP) study of selected bone marrow (BM) CD34+/lin- cells of chronic-phase CML patients at diagnosis and after 12 months of TKI nilotinib to investigate molecular signatures characterizing both conditions.

AB - BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined.OBJECTIVE: We undertook a gene expression profiling (GEP) study of selected bone marrow (BM) CD34+/lin- cells of chronic-phase CML patients at diagnosis and after 12 months of TKI nilotinib to investigate molecular signatures characterizing both conditions.

KW - Antigens, CD34/blood

KW - Bone Marrow Cells/metabolism

KW - Gene Expression Profiling/methods

KW - Gene Expression Regulation, Leukemic/drug effects

KW - Humans

KW - Leukemia, Myeloid, Chronic-Phase/blood

KW - Leukocyte Count

KW - Protein-Tyrosine Kinases/therapeutic use

KW - Pyrimidines/therapeutic use

KW - Time Factors

KW - Treatment Outcome

U2 - 10.3233/CBM-170209

DO - 10.3233/CBM-170209

M3 - Article

C2 - 29036785

VL - 21

SP - 41

EP - 53

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 1

ER -

Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

Abstract

Keywords

Access to Document

Fingerprint

Cite this